News
The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...
Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...
Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...
AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...
The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...
Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...
Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...
That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...
France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...
US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has made his first testimonies in front of Congress since he ...
It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...
Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results